Announcement on Election of Employee Director
Filed with SSE · · 2 pages · Chinese
Beijing Konruns Pharmaceutical Co., Ltd. on 6ix
Earlier from Beijing Konruns Pharmaceutical
- Announcement on FDA Approval for Clinical Trials of KC1086 Project
- Announcement on Company Re-certified as High-tech Enterprise
- Announcement on Resolutions of the 18th Meeting of the 4th Board of Supervisors
- Announcement on Implementing Repurchase and Cancellation under 2023 Restricted Stock Incentive Plan
- Announcement on Convening the Q3 2025 Performance Briefing
Later from Beijing Konruns Pharmaceutical
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
- Earnings Preannouncement for 2025
- Announcement on Using Partial Idle Raised Funds for Cash Management and Redemption
- Announcement on the Receipt of Clinical Trial Notification for KC1036 Combined with PD-1/PD-L1 Antibody in the Treatment of Advanced Solid Tumors
- Announcement on KC1036 Obtaining CDE Approval for Pivotal Phase III Clinical Study in Advanced Thymic Carcinoma
Follow Beijing Konruns Pharmaceutical into a list and get an email when it puts out news.
Follow Beijing Konruns Pharmaceutical